NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

EyePoint, Inc. (EYPT) Stock Analysis

EyePoint, Inc. (EYPT) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

EYPT

$4.58

+$0.01 (+0.22%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare EYPT with… →

EYPT Key Statistics

As of Sep 4, 2026
Trading
Open
$4.53
Previous Close
$4.57
Day's Range
4.49–4.69
52-Week Range
3.95–19.11
Volume
1.90M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.64
Valuation
Market Cap
$383.99M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
137.73
EPS (ttm)Profit attributable to each share over the last twelve months.
−3.76
Financials (FY)
Revenue (FY)
$31.37M−27.50%
Net Income (FY)
−$231.96M
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
83.84M
1-Year Return
−61.45%
Dividend and dates
Earnings Date
November 4, 2026estimated
Avg Volume
3.33M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

EYPT Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−74.93%
2025+145.23%
2024−67.76%
2023+560.29%
2022−71.41%
2021+86.02%
2020−57.55%
2019−17.99%
2018+75.00%
2017−36.84%
2016 (partial year)−56.38%

As of September 4, 2026.

EYPT Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$31.37M−$231.96M−739.4%
2024$43.27M−$130.87M−302.4%
2023$46.02M−$70.80M−153.8%
2022$41.40M−$102.25M−247.0%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$31.37M$29.31M−$243.43M−$231.96M−739.4%
2024$43.27M$39.56M−$145.85M−$130.87M−302.4%
2023$46.02M$41.39M−$75.07M−$70.80M−153.8%
2022$41.40M$33.08M−$78.94M−$102.25M−247.0%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

EYPT Valuation vs Biotechnology Median

Median of 656 stocks
MetricEYPTBiotechnology medianvs median
P/S ratio137.7315.269.0x the median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

EyePoint, Inc. (EYPT) carries a market capitalisation of $383.99M. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 214 employees.

EYPT last closed at $4.58 on September 4, 2026. That is +$0.01 (+0.22%) against the previous close. The 52-week range on file runs from $3.95 to $19.11. The latest close sits 15.95% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $31.37M. That is −27.50% against the prior fiscal year, when revenue was $43.27M. The same year closed with a net loss of $231.96M. Profit margin runs at 0%. Earnings per share on a trailing basis come to −3.76.

Across the 4 fiscal years on file, revenue moves from $41.40M in 2022 to $31.37M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. The price-to-sales ratio is 137.73. On price-to-sales that is 9 times the Biotechnology median of 15.26. 656 Biotechnology companies report these metrics, and the medians quoted come from that group.

The trailing one-year price return is −61.45%. Across 10 years the annualized return works out at −18.85%. The reported beta is 1.64. Daily returns over the trailing 10 years annualize to a volatility of 102.85%.

Growth & Income

No dividend is on file for EYPT.

The strongest complete calendar year on file is 2023 at +560.29%; the weakest is 2022 at −71.41%. Of the 9 complete calendar years on file, 4 finished higher. So far in 2026 the price is −74.93%.

Peer Comparison

EyePoint, Inc. (EYPT) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
EyePoint, Inc. EYPT $383.99M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. EyePoint, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About EyePoint, Inc.

EyePoint, Inc. engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is DURAVYU, an investigational sustained delivery treatment for vascular endothelial growth factor mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E that is in pre-clinical development phase for potentially improve outcomes in serious retinal diseases. The company was formerly known as EyePoint Pharmaceuticals, Inc. and changed its name to EyePoint, Inc. in December 2025. EyePoint, Inc. was founded in 2000 and is headquartered in Watertown, Massachusetts.

Visit website →